Please use this identifier to cite or link to this item:
http://dspace.mediu.edu.my:8181/xmlui/handle/123456789/4428Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Hepburn N | - |
| dc.date | 2003 | - |
| dc.date.accessioned | 2013-05-30T11:12:13Z | - |
| dc.date.available | 2013-05-30T11:12:13Z | - |
| dc.date.issued | 2013-05-30 | - |
| dc.identifier | http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2003;volume=49;issue=1;spage=50;epage=4;aulast=Hepburn | - |
| dc.identifier | http://www.doaj.org/doaj?func=openurl&genre=article&issn=00223859&date=2003&volume=49&issue=1&spage=50 | - |
| dc.identifier.uri | http://koha.mediu.edu.my:8181/jspui/handle/123456789/4428 | - |
| dc.description | Leishmaniasis is a major world health problem, which is increasing in incidence. In Northern Europe it is seen in travellers returning from endemic areas. The protozoa is transmitted by sandflies and may produce a variety of clinical syndromes varying from a simple ulcer to fatal systemic disease. This review considers the management of simple cutaneous leishmaniasis. Patients usually have a single ulcer that may heal spontaneously, requiring only topical, or no treatment at all. Lesions caused by Leishmania braziliensis may evolve into the mucocutaneous form, ′espundia′, and should be treated with systemic antimony. Sodium stibogluconate 20mg/kg/day i.v. for 20 days is the appropriate first line treatment in these cases. Although it may cause transient bone marrow suppression, liver damage, a chemical pancreatitis, and disturbances in the electrocardiogram, it appears safe. The success of treatment should be assessed 6 weeks after it has been completed and patients should be followed up for 6 months. | - |
| dc.publisher | Medknow Publications | - |
| dc.source | Journal of Postgraduate Medicine | - |
| dc.subject | Animal | - |
| dc.subject | Antimony Sodium Gluconate | - |
| dc.subject | therapeutic use | - |
| dc.subject | Antiprotozoal Agents | - |
| dc.subject | therapeutic use | - |
| dc.subject | Cryotherapy | - |
| dc.subject | Human | - |
| dc.subject | Leishmania | - |
| dc.subject | classification | - |
| dc.subject | Leishmaniasis | - |
| dc.subject | Cutaneous | - |
| dc.subject | diagnosis | - |
| dc.subject | epidemiology | - |
| dc.subject | pathology | - |
| dc.subject | therapy | - |
| dc.subject | Meglumine | - |
| dc.subject | therapeutic use | - |
| dc.subject | Organometallic Compounds | - |
| dc.subject | therapeutic use | - |
| dc.title | Cutaneous leishmaniasis: an overview. | - |
| Appears in Collections: | Health Sciences | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.